AMAG Pharmaceuticals Inc. (AMAG)
Symbol Info
Listed Symbol AMAG
Name AMAG Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $502,821,000
Latest Fiscal EPS $-1.92
Price Info
21 Day Moving Average $11.8814
21 Day EMA $11.615640
50 Day Moving Average $11.3264
50 Day EMA $11.296040
200 Day EMA $12.520280
200 Day Moving Average 12.074800
52 Week High $23.77
52 Week Low $6.81
52 Week Change $-48.865700
Alpha -0.006754
Beta 0.3771
Standard Deviation 0.167066
R2 0.006016
Periods 60
Share Information
10 Day Average Volume 626,288
20 Day Average Volume 698,129
30 Day Average Volume 766,674
50 Day Average Volume 1,237,977
Outstanding Shares 33,909,783
Float Shares 31,925,462
Percent Float 94.15%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 395
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 3,702,341
Institute Holdings Percent -
Institute Sold Previous 3 Months 6,803,638
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 5.90%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,984,321
Price Change
7 Day Price Change $-0.4499998
7 Day Percent Change -3.91%
21 Day Price Change $-2.045
21 Day Percent Change -15.62%
30 Day Price Change $-1.585
30 Day Percent Change -12.55%
Month To Date Price Change $-0.505
Month To Date Percent -4.37%
90 Day Price Change $1.815001
90 Day Percent Change 19.66%
Quarter To Date $-0.505
Quarter To Date Percent -4.37%
180 Day Price Change $-1.425
180 Day Percent Change -11.43%
200 Day Price Change $-1.055
200 Day Percent Change -8.72%
Year To Date $-4.145
Year To Date Percent -27.29%
Profile
Description AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
Details
Issue Type CS
Market Cap $374,533,553
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 33,909,783
CEO William K. Heiden
Employees 467
Last Audit UQ
Classification
CIK 0000792977
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1100 Winter Street
Waltham, MA 2451
Website http://www.amagpharma.com
Facisimile +1 617 649-1654
Telephone +1 617 498-3300
Email llennox@amagpharma.com
Key Ratios
Profitability
EBIT Margin -82.6
EBITDA Margin -67.4
Pre-Tax Profit Margin -18.2
Profit Margin Cont -25.37
Gross Margin 67.60
Profit Margin TOT -25.51
Income Statements
Revenue $1,039,428,000
Revenue Per Share $30.6527
Revenue 3 Years $12.32
Revenue 5 Years $42.99
Valuation Measures
PE Ratio -
Enterprise Value $407,311,993
Price To Sales 0.360327
Price To Free Cash -3.1
PE High Last 5 Years -
Price To Book 0.8
Price To Cash Flow 6.3
PE Low Last 5 Years -
Price To Tangible Book -3.3
Financial Strength
Total Debt To Equity 0.6
Int Coverage -9.2
Current Ratio 1.6
Leverage Ratio 1.9
Quick Ratio 1.4
Long Term Debt To Capital 0.35
Assets
Receivables Turnover 4.5
Invoice Turnover 4.40
Assets Turnover 0.30
Management Effectiveness
Return Assets -16.44
Return On Equity -38.22
Return On Capital -19.17
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AMAG
AMAG Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.